1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Imagenetix, Inc.

Imagenetix, Inc.

IAGX
Imagenetix, Inc.US flagOther OTC
0.00
USD
- -
- -
5,685.00Market Cap
Imagenetix, Inc.
IAGX
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

1999
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2013
2015
TTM
FRC
- -
0.58
0.52
0.4
0.53
0.83
0.72
0.52
0.51
0.68
0.6
0.61
- -
- -
0.25
Revenue per Share
- -
-0.05
-0.03
-0.09
0.05
0.08
-0.06
-0.06
-0.16
0.04
-0.06
-0.19
- -
- -
-0.35
Basic EPS, GAAP
- -
-0.05
-0.03
-0.01
0.01
-0.02
-0.03
-0.08
-0.01
0.02
-0.03
-0.18
- -
- -
0.06
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.02
-0.04
-0.06
-0.15
-0.1
-0.01
-0.51
-0.57
-0.83
-0.78
-0.84
-0.98
- -
- -
-1.28
Book Value per Share
- -
0.17
0.15
0.11
0.18
0.46
0.45
0.43
0.32
0.37
0.31
0.17
- -
- -
-0.13
Tangible Book Value per Share
4
8
9
9
9
9
11
11
11
11
11
12
- -
- -
12
Basic Weighted Avg Shares
- -
5
4
3
5
8
8
6
6
7
7
7
- -
- -
3
Sales/Revenue/Turnover
-928,600
-6.86
-4.29
-20.43
12.67
13.72
-16.04
-14.88
-40.03
-12.32
-34.54
-46.39
- -
- -
-41.92
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-1
- -
1
-1
-1
-2
- -
-1
-2
- -
- -
-4
Net Income, GAAP
- -
- -
- -
- -
15.29
26.19
- -
- -
- -
51.64
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-928,700
-7.76
-5.76
-22.75
10.18
9.95
-7.76
-11.93
-31.9
5.76
-10.57
-30.41
- -
- -
-138.22
Profit Margin (%)
- -
1
1
1
1
4
4
4
3
4
3
- -
-5
- -
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
1
1
1
2
4
5
5
3
4
4
2
-5
6
-1
Total Equity
- -
- -
- -
- -
32.4
24.7
- -
- -
- -
-11.73
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
-55.09
-303.73
- -
- -
- -
-4.89
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'13
Sep'13
Dec'13
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
3
2
1

Working Capital

FRC

•

in mil. unless spec.
Jun'13
Sep'13
Dec'13
Total Current Assets
3
2
2
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
1
1
- -
Inventories
1
1
1
Total Current Liabilities
4
3
3
Payables & Accruals
1
1
1
ST Debt
1
1
1
Deferred Revenue
2
2
2

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-38.99%
-120.98%
-225.33%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
Similar Companies
Swedish Orphan Biovitrum AB (publ) (BIOVF)
Lobe Sciences Ltd. (LOBEF)
ECO Animal Health Group plc (EAH.L)
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)
Street Capital Inc. (REZNF)
4Front Ventures Corp. (FFNTF)
Business
Imagenetix, Inc. develops, formulates, and markets proprietary and natural-based bioceutical products, including nutritional supplements and over-the-counter topical creams and skin care products. Its core products include scientifically tested formulations such as Celadrin, a fatty acid ester compound for joint health, as well as other oral supplements, creams, and specialized products targeting inflammation, obesity, periodontal disease, and mitochondrial support. The company operates through multiple distribution channels including direct sales, mass marketing, nutritional and medical professionals, retail, direct response media, and strategic partnerships across North America, Europe, and Asia. Founded in 1996 and headquartered in San Diego, California, Imagenetix focuses on research-backed innovations to improve health, particularly in areas related to inflammation and oxidative stress. Recent developments include active strategic alliances aimed at expanding medical applications and commercialization of its ingredient technologies, as well as a continued emphasis on clinical validation and collaborative research to advance product efficacy and safety. Key offerings such as the undenatured type II collagen ingredient UC-II® and stable calcium folinate Mitafolin® illustrate its product diversification and innovation within the nutraceutical sector. The company leverages proprietary intellectual property licensing and turnkey services encompassing product development, regulatory compliance, manufacturing, and marketing support to enhance its market presence and product pipeline growth. This comprehensive positioning highlights Imagenetix's commitment to expanding its scientific and commercial footprint in natural health solutions with recent operational focus on partnerships, ingredient innovation, and global market expansion.